
Translate your IBD therapeutics to the clinic with well-characterized in vivo models to understand the preclinical efficacy of Crohn’s disease (CD) and ulcerative colitis (UC) agents. Select well established preclinical models with diverse mechanisms capturing the distinct clinical and pathological features of IBD:
Figure 1: Disease Activity Index: Stool consistency score + stool blood score + body weight score.
Disease activity index measured in naïve vs animals administered DSS + vehicle or CsA
Figure 2: Effects of prophylactic treatment of the calcineurin inhibitor CsA orally
once daily improves colon weight:length ratio in a DSS-induced mouse model
Figure 3: Inflammation, epithelial erosion, and submucosal edema in
naïve vs. animals administered DSS + vehicle or varying levels of CsA
Figure 4: Effects of anti-IL-12 treatment in a T cell transfer mouse model
Benefit from an experienced scientific team to support and streamline your research with:
Typical in-life study measurements include:
Major endpoints:
© 2023 Crown Bioscience. All Rights Reserved.
© 2023 Crown Bioscience. All Rights Reserved. Privacy Policy